Literature DB >> 22615645

Evaluation of the use of partition coefficients and molecular surface properties as predictors of drug absorption: a provisional biopharmaceutical classification of the list of national essential medicines of Pakistan.

R Shawahna1, Nu Rahman.   

Abstract

BACKGROUND AND THE PURPOSE OF THE STUDY: Partition coefficients (log D and log P) and molecular surface area (PSA) are potential predictors of the intestinal permeability of drugs. The aim of this investigation was to evaluate and compare these intestinal permeability indicators.
METHODS: Aqueous solubility data were obtained from literature or calculated using ACD/Labs and ALOGPS. Permeability data were predicted based on log P, log D at pH 6.0 (log D(6.0)), and PSA.
RESULTS: Metoprolol's log P, log D(6.0,) and a PSA of <65 Å correctly predicted 55.9%, 50.8% and 54.2% of permeability classes, respectively. Labetalol's log P, log D(6.0) and PSA correctly predicted 54.2%, 64.4% and 61% of permeability classes, respectively. Log D(6.0) correlated well (81%) with Caco-2 permeability (P(app)). Of the list of national essential medicines, 135 orally administered drugs were classified into biopharmaceutical classification system (BCS). Of these, 57 (42.2%), 28 (20.7%), 44 (32.6%), and 6 (4.4%) were class I, II, III and IV respectively.
CONCLUSION: Log D(6.0) showed better prediction capability than log P. Metoprolol as permeability internal standard was more conservative than labetalol.

Entities:  

Keywords:  Biopharmaceutical classification system; PSA; Permeability; log D; log P

Year:  2011        PMID: 22615645      PMCID: PMC3232101     

Source DB:  PubMed          Journal:  Daru        ISSN: 1560-8115            Impact factor:   3.117


INTRODUCTION

Systemic bioavailability of an orally administered drug is largely dependent on its physicochemical properties and dosage formulation factors (1). Sophisticated modeling of the kinetics and dynamics of drug processes in the gastrointestinal tract subsequently led to the advent of the biopharmaceutical classification system (BCS) (2). According to the biowaiver, any possible variation in the bioavailability of a rapidly dissolving and highly soluble drug is attributed to physiological conditions rather than formulation and hence there is no logic in conducting a bioequivalence testing for such formulation (2). BCS offers a framework for development of pharmaceutical formulations. It has been estimated that the pharmaceutical industry can save $35 million annually through the applications of BCS (3). Assignment of the solubility and permeability classes of a drug is a laborious task. Lately, computational models to predict aqueous solubility and permeability through biological membranes have received considerable attention. The use of physicochemical properties in predicting in vivo behavior of drugs has many advantages including cost reduction; better control over protocol, reproducibility and avoidance of risk presented to human volunteers usually encountered in the bioequivalence studies (4). Molecular surface properties and partition coefficients have been used actively in construction of quantitative structure activity relationship (QSAR) models to predict intestinal permeability (2, 5-6). This study reports for the first time an evaluation and comparison of pH-dependent and pH-independent n-octanol/water partition coefficients (log D and log P) and polar surface area (PSA) in prediction of intestinal permeability of drugs. The log D at physiologically relevant pH of 6.0 (log D6.0) was used to provisionally classify the orally administered drugs on the list of national essential medicines (NEML) of Pakistan into BCS.

MATERIAL AND METHODS

The present revision of the NEML contains 335 medicines of different pharmacological classes (7). The highest dose of drug products available in oral dosage forms, i.e. oral tablets and capsules, were used.

Solubility

The dose number (Do) was calculated using equation 1: Where Mo is the highest dose strength (in mg), Cs is the solubility (mg/ml), and Vo equals to 250 ml (8). The most conservative data measures were used and experimental aqueous solubility data triumphed over predicted data. Experimental solubility data were obtained from Yalkowsky & He (9) and Drugbank (10) which in the later, data were originally from (11). Data reporting the pH and temperature at which the aqueous solubility of the compound was measured were favored. Solubility data for the rest of the drugs were calculated using ACD/Labs (ACD/Labs, version 6.0; Advanced Chemistry Development: Toronto, Canada) and ALOGPS (ALOGPS, version 2.1. The Virtual Computational Chemistry Laboratory, VCCLAB, Germany). The ionization constant (pKa) values were obtained from the literature (12).

Permeability

Log D and log P are linked through the equations 2 and 3: For acids: For bases: Both log P and log D values were calculated using ACD/Labs. Similarly, PSA values were estimated using ACD/Labs.

RESULTS AND DISCUSSION

Previously the orally administered drugs on the World Health Organization (WHO) essential medicine list (EML) were provisionally classified into BCS (13, 14). The NEML contained 135 orally administered drugs. It has been emphasized that the maximal administered dose to solubility ratio has a central role in the BCS (15). The NEML contained 89 drugs in common with the WHO's EML while in term of doses, only 46 were similar (Table 1).
Table 1

BCS classification of the orally administered drugs on the list of national essential medicines (NEML) of Pakistan with their therapeutic classes, maximum doses, experimental water solubility, predicted aqueous solubility (ACD/Labs), pH dependent solubility (pKa), log D, calculated PSA, and interaction with transporters in the intestine.

Provisional biopharmaceutical classification of drugs on the list of national essential medicines (NEML) of Pakistan.

SolubilityPermeabilityBCS classification



DrugTherapeutic classMaximum dose (mg)Do1Do2Do3pKaLog D6.0PSA ¥Transporters interactionSolubility classPermeability classBCS Class

HABH+
Acetylsalicylic acidNSAID300NA0.00123.48−1.2463.6PgpHighLowIII
AcyclovirAntiviral200NA2.19.181.89−1.76109.83OATP1, OATP3, OCT1LowLowIV
AlbendazoleAnthelmintic200NA13.310.465.622.8792.31BCRPLowHighII
Allopurinolanti-gout300NA0.039.22.4−3.8174.69NAHighLowIII
AmilorideDiuretic5NA0.168.581.581.07156.79NAHighHighI
AminophyllineAntiasthmatic200NA0.00002NANA192NAHighLowIII
AmiodaroneAntiarrhythmic2001.19.376.2942.7MDR1LowHighII
AmitryptylineAntipsychotic50NA0.149.242.083.24NAHighHighI
AmlodipineAntihypertensive5NA0.0018.731.4399.9MDR1HighHighI
AmoxicillinAntibacterial500NA6.662.616.93−1.93158.26PEPT1LowLowIV
Amphotericin BAntifungal1000.53.968.13NA320NAHighLowIII
AmpicillinAntibacterial5000.22.616.79−1.21138PEPT1, OCTN2HighLowIII
AnastrozoleAnticancer1NA0.0084.780.7778.3NAHighHighI
AtenololAntihypertensive100NA0.000413.889.17−2.7384.58MDR1HighLowIII
Atropine sulphateAntispasmodic1NA6.76E-069.88−1.5249.77NAHighLowIII
AzathioprineAnticancer501.50.25−0.54143NALowLowIV
BromocriptineAntiparkinsonism2.5NA0.119.616.454.52118MDR1HighHighI
BusulphanAnticancer0.5NA1.20E-07NA−0.52104NAHighLowIII
BaptoprilAntihypertensive50NA0.00023.82−2.0296.41MDR1: PEPT1HighLowIII
CarbamazepineAntiepileptic200NA1013.942.6746.33MDR1LowHighII
CarbidopaAntiparkinsonism25NA0.13.47.91−2.71116NAHighLowIII
CefiximeAntibacterial100NA0.032.12.86−3.72238NAHighLowIII
CefuroximeAntibacterial250NA3.522.59−4.47199PEPT1LowLowIV
CephalexinAntibacterial5000.043.126.8−2.22138PEPT1, PEPT2,OCTN2HighLowIII
CephradineAntibacterial5000.253.126.99−1.53138OAT1, OCTN2, PEPT1HighLowIII
ChlorambucilAnticancer20.014.863.661.5240.5MRP1HighHighI
ChloramphenicolAntibacterial250NA4.311.031.02115.38NALowHighII
ChloroquineAntimalarial150NA0.0210.481.228.16MDR1HighHighI
ChlorpheniramineAntiallergic4NA0.00039.330.4916.13NAHighHighI
ChlorpromazineAntipsychotic100NA0.449.432.2831.78MDR1, OCT1HighHighI
CimetidineAntiulcer400NA0.146.73−1.14114.19MDR1, OAT1, OAT3, OCT1, OCT3, OCTN2HighLowIII
CiprofloxacinAntibacterial250NA0.772.748.76−1.0772.88MDR1HighLowIII
ClofazimineAntileprosy100NA412.46.245.7239.99MDR1LowHighII
ClomipramineAntipsychotic25NA0.099.492.586.48MDR1HighHighI
ClofazimineAntileprosy100NA412.46.245.7239.99MDR1LowHighII
CloxacillinAntibacterial250NA0.07NA−0.81138.04PEPT1HighLowIII
Colchicineanti-gout0.5NA0.03NA0.9283.09MDR1, OCT3HighHighI
CyclizineAntihistamine50NA0.27.461.836.5NAHighHighI
CyclophosphamideAnticancer50NA0.0024.090.2351.38MDR1HighHighI
CyclosporinImmunosuppressent10010NANA279BCRP, MDR1, MRPs, OATP1B1LowLowIV
DapsoneAntileprosy50NA0.571.240.9494.56NAHighHighI
DexamethasoneAntiallergic0.5NA0.0412.141.8794.83MDR1, OATP1A2HighHighI
DiazepamSedative10NA23.42.9632.67MDR1LowHighII
Didanosine (ddi)Antiretroviral400NA0.818.671.98−1.3383.81NAHighLowIII
DigoxinCardiostimulant0.25NA0.00213.50.85203.06MDR1, OATP1B3, OATP1C1, OATP4C1, OSTHighHighI
DiloxanideAnti-Amoebic500NA1.08NA1.6240.54NALowHighII
DiltiazemCalcium channel blocker180NA0.0068.912.6484.4MDR1HighHighI
DoxycyclineAntibacterial100NA0.544.59.32−3.06181.62OAT1, OAT3, OAT4HighLowIII
EfavirenzAntiretroviral50NA376.67.924.8438.33NALowHighII
EnalaprilAntihypertensive10NA0.0023.755.5−0.1295.9MDR1, OATP1A2, PEPT1HighHighI
ErgometrineOxytotic0.25NA0.00018NA−0.5468.36MDR1HighLowIII
ErgotamineAntimigraine1NA0.49.627.21.99118.21MDR1HighHighI
ErythromycinAntibacterial500NA0.0813.088.140.72193.91MDR1, MRP1, OAT2, OATP1A2HighHighI
EthambutolAnti-tuberculosis400NA0.00169.6−3.2364.52NAHighLowIII
EthosuximideAntiepileptic250NA0.0429.70.3846.17NAHighHighI
EtoposideAnticancer10029.951.96161BCRP, MDR1−3,6,7,LowHighII
FluoxetineAntipsychotic20NA0.00210.05NA21.3MDR1HighHighI
FlutamideAnticancer250NA0.4213.12NA74.9NAHighHighI
FurosemideDiuretic40NA0.023.040.26131.01MRP2, OAT1, OAT3, OAT4, OCTN2HighHighI
GemfibrozilAntihyperlipidemia300NA0.124.752.1446.5NAHighHighI
GlibenclamideAntidiabetic5NA1NA2.75121.98BSEP, MDR1, MRP1, OATP2B1HighHighI
GriseofulvinAntifungal500NA2985.07NA3.5371.06NALowHighII
HaloperidolAntipsychotic5NA0.00613.98.250.8240.54MDR1HighHighI
HydralazineAntihypertensive25NA0.08NA0.5663.83NAHighHighI
HydrochlorthiazideDiuretic50NA0.488.95−0.07135.12NAHighHighI
IbuprofenNSAID600NA1.174.412.1237.3MDR1, MRP1, MRP3, OAT1−4LowHighII
ImipramineAntipsychotic255.59.491.856.5MDR1, OCT2, OCT3LowHighII
IndinavirAntiretroviral400NA53.35.732.76118.03MDR1, MRP1, MRP2, OATP1A2, OATP1B1LowHighII
IndomethacinNSAID256.254.170.368.5MDR1, MRP1-8, OAT1-4LowHighII
IsoniazidAnti-tuberculosis300NA0.0111.273.79−0.8968.01NAHighLowIII
Isosorbide dinitrateAntianginal10NA4.82E-05NA−1.7558.92NAHighLowIII
LabetalolAntihypertensive200NA0.047.919.2−0.4295.6NAHighHighI
Lamivudine (3tc)Antiretroviral150NA0.1713.834.41−0.71113.45BCRP, MRP1HighLowIII
LevamisoleAnthelmintic40NA0.00678.81−0.1540.9NAHighHighI
LevodopaAntiparkinsonism250NA0.092.249.3−0.27103.78NAHighHighI
LisinoprilAntihypertensive20NA0.022.1810.51−1.32133MDR1, PEPT1HighLowIII
LosartanAntihypertensive25NA0.494.243.10.8992.5MDR1, OAT1HighHighI
MebendazoleAnthelmintic100NA2010.295.022.7784.08MDR1LowHighII
MercaptopurineAnticancer500.038.462.40.3785.2MRP4, MRP5HighHighI
MetforminAntidiabetic500NA0.00213.1−4.3188.99OCT1, OCT2HighLowIII
MethionineAntidote250NA0.042.239.26−2.1388.6OCTN2HighLowIII
MethotrexateAnticancer10NA6.20E-053.545.09NA211BCRP, MDR1, MRP1-7, OAT1-4, OATP1B1, OATP1B3, OATP1C1HighLowIII
MethyldopaAntihypertensive500NA0.32.289.3−2.37103.78PEPT1HighLowIII
MetoclopramideAntiemetic10NA0.000213.289.62−7.867.59NAHighLowIII
MetronidazoleAnti-Amoebic400NA0.22.58−1.0178.94NAHighLowIII
MorphineAnalgesic30NA0.00059.728.14−1.7752.93MDR1HighLowIII
Nalidixic acidAntibacterial500NA0.731.25.950.3370.5NAHighHighI
NelfinavirAntiretroviral250NA291.549.587.535.44127.2BCRP, MDR1, OATP1A2, OATP1B1LowHighII
NeostigmineAntidote15NA0.00019NA−3.0329.54MDR1HighLowIII
NevirapineAntiretroviral200NA1.3710.934.741.8458.12NALowHighII
NiclosamideAnthelmintic500NA1801.8NA5.495.15NALowHighII
NitrofurantoinAntibacterial100NA0.287.691.2−0.41120.73NAHighHighI
NitroglycerinAntianginal6.40.02NA2.22165NAHighHighI
NystatinAntifungal200NA26.6NA−0.42319.61NALowHighII
OmeprazoleAntiulcer20NA0.0049.084.612.1596.3BCRP, MDR1, MRP3HighHighI
ParacetamolAnalgesic500NA0.199.860.3449.33NAHighHighI
PenicillamineAntidote250NA0.0962.1311.54−1.57102.12NAHighLowIII
PhenobarbitalAntiepileptic30NA0.187.881.6675.27NAHighHighI
PhenoxymethylpenicillinAntibacterial500NA0.022.62−1.47121.24NAHighLowIII
PhenytoinAntiepileptic100NA48.332.5258.2MDR1, MRP2LowHighII
PrazosinAntihypertensive2NA0.0166.47−1.25107BCRP, MDR1, OCT1−3HighLowIII
PrednisoloneAntiallergic5NA0.1512.471.4994.83MDR1HighHighI
PrimaquineAntimalarial7.5NA0.0001510.38−0.4160.17NAHighHighI
ProcainamideAntiarrythmic250NA0.0179.86−1.4358.4MDR1, OATP1A2, OCT1-3, OCTN1,2HighLowIII
ProcarbazineAnticancer50NA0.00067.460.1153.2NAHighHighI
ProchlorperazineAntipsychotic51.347.822.4235NALowHighII
ProcyclidineAntiparkinsonism5NA2.0310.480.8423.5NALowHighII
PromethazineAntiallergic25NA0.048.982.0431.78MDR1HighHighI
PropranololAntihypertensive160NA0.0113.849.140.2841.49MDR1, NTCP, OCT2HighHighI
PropylthiouracilAnticancer100NA0.27.630.541.3673.22NAHighHighI
PyrantelAnthelmintic250NA0.01210.97−0.4943.84NAHighLowIII
PyrazinamideAnti-tuberculosis500NA0.0913.91−0.3768.87NAHighHighI
PyridostigmineMuscle relaxant60NA0.0005NA−4.3129.54NAHighLowIII
QuinidineAntiarrythmic2005.713.059.131.3545.6BSEP, MDR1, OAT3, OATP1A2, OATP1B1, OCT1,2, OCTN1,2LowHighII
QuinineAntimalarial200NA0.0313.059.130.5445.59MDR1, OATP1A2, OATP1C1, OCT1,2, OCTN1,2HighHighI
RisperidoneAntipsychotic3NA0.0177.911.0161.9 NAHighHighI
RifampicinAnti-tuberculosis600NA1.71NA−1.75217MDR1, MRP1,2,5, OATP1A2, OATP1B1, OATP1B3, OATP2B1LowLowIV
RitonavirAntiretroviral100NA1063.8110473.485.28202.26BCRP, MDR1, MRP1,2, OATP1A2, OATP1B1LowHighII
SalbutamolAntiasthmatic4NA0.0000169.839.22−2.8472.72NAHighLowII
SaquinavirAntiretroviral200NA16NA2.84166.75BCRP, MDR1,2, OATP1A2, OATP1B1LowHighII
SelegilineAntiparkinsonism5NA 0.78 7.530.787.531.423.2MDR1HighHighI
SpironolactoneDiuretic100NA44.3NA3.1285.74MDR1LowHighII
Stavudine (D4T)Antiretroviral40NA0.0099.57−0.8678.87NAHighLowIII
SulphasalazineAntibacterial500NA0.292.881.860.35149.69NAHighHighI
TamoxifenAnticancer20NA479.048.696.212.5BCRP, BSEP, MDR1LowHighII
TheophyllineAntiasthmatic270NA0.258.61.05−0.1869.3NAHighHighI
ThioacetazoneAnti-tuberculosis50NA0.2NANA112NAHighLowIII
Thioguanine (6 thioguanine)Anticancer40NA0.0047.443.09−0.4111MRP4HighHighI
TinidazoleAntifungal500NA0.0004NA−0.27106NAHighHighI
TrifluperazineAntipsychotic5NA1.637.824.0435NALowHighII
TrimethoprimAntibacterial300NA0.177.34−0.42105.51MDR1HighHighI
Valproic acidAntiepileptic300NA0.0054.82−1.65100.27OAT3, OCTN2HighLowIII
VerapamilAntihypertensive240NA0.859.032.9164BCRP, BSEP, MDR1, MRP1-4,7, OATP1A2, OCT1, OCTN1,2, PGPHighHighI
WarfarinAnti-coagulant5NA0.014.51.9163.6NAHighHighI
Zalcitabine (DDC)Antiretroviral0 75NA4.96E-074.47−1.5188.2NAHighLowIII
Zidovudine (ZDV)Antiretroviral100NA0.1NA−0.5391.23PEPT1HighLowIII

-Do (dose number) calculated from solubility data taken from ref. (9)

Do (dose number) calculated from solubility data taken from ref. (10)

Do (dose number) calculated from predicted solubility data, ACD/Labs

The maximal dose strength on the list of national essential medicines of Pakistan;

pKa values were taken from ref. 12

Calculated log D6.0 values at pH 6 using ACD/Labs

PSA calculated from ACD/Labs

Transporter interaction taken from ref. 25

BCRP: Breast cancer resistance protein

BSEP: Bile salt export pump; MDR: Multidrug transporter

MRP: Multidrug resistance protein; NA: not available

OAT: Organic anion transporter

OATP: Organic anion-transporting polypeptide

OCTN: Organic cation transporter

OST: Organic solute transporter

PEPT: Peptide transporter

Pgp: P-glycoprotein.

BCS classification of the orally administered drugs on the list of national essential medicines (NEML) of Pakistan with their therapeutic classes, maximum doses, experimental water solubility, predicted aqueous solubility (ACD/Labs), pH dependent solubility (pKa), log D, calculated PSA, and interaction with transporters in the intestine. -Do (dose number) calculated from solubility data taken from ref. (9) Do (dose number) calculated from solubility data taken from ref. (10) Do (dose number) calculated from predicted solubility data, ACD/Labs The maximal dose strength on the list of national essential medicines of Pakistan; pKa values were taken from ref. 12 Calculated log D6.0 values at pH 6 using ACD/Labs PSA calculated from ACD/Labs Transporter interaction taken from ref. 25 BCRP: Breast cancer resistance protein BSEP: Bile salt export pump; MDR: Multidrug transporter MRP: Multidrug resistance protein; NA: not available OAT: Organic anion transporter OATP: Organic anion-transporting polypeptide OCTN: Organic cation transporter OST: Organic solute transporter PEPT: Peptide transporter Pgp: P-glycoprotein.

Solubility correlation and class assignment

Lindenberg and colleagues classified 61 drugs with certainty on the basis of reliable practical solubility data. A total of 59 drugs were in common with Lindenberg's list (13). ACD/Labs calculated solubility and predicted correctly that 51 (86.4%) of the solubility classes; whereas, data obtained from Drugbank and ALOGPS could correctly predict 76.3% and 78% of the drugs classified, respectively (Supplementary table 1). Solubility class assignment was compared to the WHO solubility classification (16). Of the 80 drugs in common, 66 drugs (82.5%) were classified in the same solubility classes, whereas, of the 14 drugs for which the solubility classes were different, 6 drugs were classified based on incomplete/ inconclusive data and 3 drugs had higher or lower doses on the NEML as compared to the WHO's EML (Supplementary table 2).
Supplementary table 1

Solubility data correlation: ACD/Labs, experimental water solubility DrugBank, ALOGPS and reliable experimental solubility.

DrugDose (mg)D1D2D3Solubility Class 1Solubility Class 2Solubility Class 3Reliable experimental solubilityΘ
Abacavir3002.92682930.01558440.99173554LowHighHighHigh
Acetylsalicylic Acid5000.0020.43478261.36986301HighHighLowHigh
Aciclovir2002.10526320.49382720.08810573LowHighHighHigh
Allopurinol1000.01018070.70298770.06802721HighHighHighHigh
Amiloride50.16666670.01639344HighHighHigh
Atenolol1000.00040.02962960.93240093HighHighHighHigh
Captopril250.00010.02212389HighHighHigh
Carbamazepine2001045.197745.26315789LowLowLowLow
Chloramphenicol2504.34782610.42.1691974LowHighLowHigh
Chloroquine1500.022034556.60377434.2857143HighLowLowHigh
Cimetidine2000.07220220.160.98039216HighHighHighHigh
Cloxacillin10000.2805049287.7697875.1879699HighLowLowHigh
Codeine300.00228220.01333330.20797227HighHighHighHigh
Colchicine0.50.02857144.44E-050.07246377HighHighHighHigh
Cyclophosphamide250.00116820.0020.00662252HighHighHighHigh
Dapsone1001.14285711.05263161.4084507LowLowLowLow
Diazepam510.41.63934426HighHighLowHigh
Digoxin0.6250.00543480.01968504HighHighHigh
Doxycycline1000.54054050.63492060.7751938HighHighHighHigh
Ergotamine10.40.01793722HighHighHigh
Fluconazole500.74074072000.14388489HighLowHighHigh
Furosemide400.023054826.6666671.3559322HighLowLowLow
Griseofulvin2501492.5373115.7407419.8412698LowLowLowLow
Hydralazine500.17241380.07575758HighHighHigh
Hydrochlorothiazide250.24390240.14285710.04464286HighHighHighHigh
Ibuprofen4000.780487832.65306123.3918129HighLowLowLow
Indinavir40053.333333106.6666733.1950207LowLowLowLow
Levodopa2500.094250723.5626770.3030303HighLowHighHigh
Levonorgestrel0.750.42075741.47058820.51457976HighLowHighHigh
Levothyroxine0.10.09975060.00380950.04454343HighHighHighHigh
Metformin5000.0020.88888889HighHighHigh
Methyldopa2500.14992510.44247788HighHighHighHigh
Metronidazole5000.281690184.4594590.008HighLowHighHigh
Nelfinavir250291.54519523.560209LowLowLow
Nifedipine101.33333332.25988701LowLowLow
Nitrofurantoin1000.28571435.03271260.96385542HighLowHighLow
Paracetamol5000.19665680.14285710.48192771HighHighHighHigh
Penicillamine2500.09680540.0090090.21505376HighHighHighHigh
Penicillin V2500.012572312.20264317HighHighLowHigh
Phenobarbital1000.6250.36036041.44927536HighHighLowHigh
Phenytoin100412.55.62587904LowLowLowLow
Prednisolone50.15384620.08968610.08368201HighHighHighHigh
Primaquine150.00031651.06382979HighLowHigh
Promethazine250.04784694.08163265HighLowHigh
Propranolol400.00296022.28571432.01511335HighLowLowHigh
Propylthiouracil500.11494250.16666670.42918455HighHighHighHigh
Pyrazinamide4000.07597340.10666670.01707577HighHighHighHigh
Pyridostigmine600.00054170.23076923HighHighHigh
Riboflavin50.00018680.23612750.0304414HighHighHighHigh
Ritonavir1001063.8298317.460317LowLowLow
Salbutamol40.0000165.33333330.00744186HighLowHighHigh
Saquinavir20016323.88664LowLowLow
Stavudine400.00913760.0160.00395062HighHighHighHigh
Sulfamethoxazole4001.5094342.62295083.48583878LowLowHighLow
Theophylline3000.28368790.240.05240175HighHighHighHigh
Thiamine500.00091260.000413.0718954HighHighLowHigh
Trimethoprim2000.11527380.06611571.30081301HighHighLowLow
Valproic Acid5000.00912580.004130.718954HighHighLowLow
Zidovudine3000.32432430.0240.07361963HighHighHighHigh

1-Do (dose number) calculated from predicted solubility data, ACD/Labs

2 Do (dose number) calculated from solubility data obtained from DrugBank database

3 Do (dose number) calculated from predicted solubility data, ALOGPS

Reliable experimental solubility, were taken from ref. 13.

Supplementary table 2

Solubility and permeability classification comparing the list of national essential medicines (NEML) of Pakistan and classification of the WHO's essential medicines model list (EML)

DrugWHO Dose (mg)NEML Dose (mg)WHO Solubility classNEML Solubility classCommentWHO Permeability classNEML Permeability classComment
Acetylsalicylic acid500300HighHighHighLowClassified as low permeability drug based on reliable data*; Log D6.0 indicated low permeability, whereas, PSA was lower than that of labetalol
Aciclovir200200HighLowLowLow
Albendazole400200LowLowinconclusiveHigh
Allopurinol100300HighHighHighLowClassified as low permeability drug based on reliable data*; log D6.0 indicated low permeability, whereas, PSA was lower than that of labetalol
Amiloride55HighHighHighHigh
Amitriptyline2550HighHighHighHigh
Amlodipine55HighHighHighHigh
Amoxicillin500500HighLowclassified as high solubility based on incomplete data*HighLowClassified as high permeability based on incomplete data*; both log D60 and PSA indicated low permeability
Atenolol100100HighHighLowLow
Carbamazepine200200LowLowHighHigh
Cefixime400100LowHighNEML dose is lower than that of WHOinconclusiveLow
Chloramphenicol250250HighLowLowHighClassified as low permeability based on reliable data*; PSA can indicate low permeability
Chloroquine150150HighHighHighHigh
Chlorphenamine44HighHighinconclusiveHigh
Chlorpromazine100100HighHighinconclusiveHigh
Ciprofloxacin250250HighHighinconclusiveLow
Clomipramine2525HighHighinconclusiveHigh
Cloxacillin1000250HighHighLowLow
Dapsone10050LowHighNEML dose is lower than that of WHOHighHigh
Diazepam510HighLowNEML dose is higher than that of WHOHighHigh
Didanosine400400HighHighLowLow
Digoxin0.250.25HighHighHighHigh
Diloxanide500500LowLowinconclusiveHigh
Doxycycline100100HighHighHighLowClassified as low permeability drug based on reliable data*; both log D6.0 and PSA indicated low permeability
Efavirenz20050LowLowinconclusiveHigh
Enalapril2.510HighHighLowHighBoth log D60 and PSA indicated high permeability
Erythromycin250500LowHighclassified as low solubility based on incomplete data*LowHighClassified as low permeability based on incomplete data*; PSA can indicate low permeability
Ethambutol400400HighHighLowLow
Furosemide4040LowHighinconclusiveHigh
Glibenclamide55LowHighClassified as low solubility based on inconclusive data*inconclusiveHigh
Griseofulvin250500LowLowHighHigh
Haloperidol25inconclusiveHighLowHigh
Hydralazine5025HighHighLowHighClassified as low permeability drug based on reliable data*; both log D60 and PSA indicated high permeability
Hydrochlorothiazide2550HighHighLowHighClassified as low permeability drug based on reliable data*; PSA can indicate low permeability
Ibuprofen400600LowLowHighHigh
Indinavir sulfate400400LowLowinconclusiveHigh
Isoniazid300300HighHighinconclusiveLow
Isosorbide dinitrate510HighHighinconclusiveLow
Lamivudine150150HighHighHighLowBoth log D60 and PSA indicated low permeability
Levamisole15040HighHighinconclusiveHigh
Levodopa250250HighHighHighHigh
Carbidopa2525HighHighinconclusiveLow
Mebendazole500100LowLowinconclusiveHigh
Dl-methionine250250HighHighHighLowClassified as high permeability based on incomplete data*; PSA can indicate high permeability
Metformin500500HighHighLowLow
Methyldopa250500HighHighLowLow
Metoclopramide1010HighHighLowLow
Metronidazole500400HighHighHighLowClassified as high permeability drug based on reliable data*; PSA can indicate low permeability
Morphine1030HighHighinconclusiveLow
Nelfinavir250250inconclusiveLowinconclusiveHigh
Neostigmine1515HighHighLowLow
Nevirapine200200LowLowHighHigh
Niclosamide500500LowLowinconclusiveHigh
Nitrofurantoin100100LowHighHighHigh
Nystatin200200inconclusiveLowinconclusiveHigh
Paracetamol500500HighHighHighHigh
Penicillamine250250HighHighLowLow
Phenobarbital10030HighHighHighHigh
Penicillin v250500HighHighHighLowClassified as high permeability drug based on reliable data*; both log D60 and PSA indicated low permeability
Phenytoin100100LowLowHighHigh
Prednisolone255HighHighHighHigh
Primaquine157.5HighHighHighHigh
Promethazine2525HighHighHighHigh
Propranolol40160HighHighHighHigh
Propylthiouracil50100HighHighHighHigh
Pyrantel250250LowHighclassified as low solubility based on inconclusive data*inconclusiveLow
Pyrazinamide400500HighHighinconclusiveHigh
Quinine300200HighHighHighHigh
Rifampicin300600LowLowHighLowClassified as high permeability based on incomplete data*; both log D6.0 and PSA indicated low permeability
Ritonavir100100LowLowinconclusiveHigh
Salbutamol44HighHighHighLow
Saquinavir200200LowLowinconclusiveHigh
Spironolactone25100inconclusiveLowinconclusiveHigh
Stavudine (d4t)4040HighHighHighLowPSA can indicate high permeability
Sulphasalazine500500LowHighclassified as low solubility based on inconclusive data*LowHighInconclusive data*; PSA can indicate low permeability
Trimethoprim200300LowHighHighHigh
Valproic acid500300HighHighHighLowClassified as high permeability drug based on reliable data*; both log 0 and PSA indicated low permeability
Verapamil80240LowHighclassified as low solubility based on inconclusive data*HighHigh
Warfarin55HighHighHighHigh
Zidovudine (zdv)300100HighHighHighLowClassified as high permeability drug based on reliable data*; PSA can indicate high permeability

Ref. (13)

Ref. (16)

Solubility data correlation: ACD/Labs, experimental water solubility DrugBank, ALOGPS and reliable experimental solubility. 1-Do (dose number) calculated from predicted solubility data, ACD/Labs 2 Do (dose number) calculated from solubility data obtained from DrugBank database 3 Do (dose number) calculated from predicted solubility data, ALOGPS Reliable experimental solubility, were taken from ref. 13. Solubility and permeability classification comparing the list of national essential medicines (NEML) of Pakistan and classification of the WHO's essential medicines model list (EML) Ref. (13) Ref. (16) Of the 135 drugs on the NEML, 15 (11.1%) drugs were classified according to their experimental solubility data obtained from Yalkowsky & He, of which 7 (46.7%) were classified as high soluble drug while the rest of 8 (53.3%) were classified as low soluble drugs. Additionally, 33 drugs (24.4%) were classified based on the solubility data obtained from Drugbank. Of these, 29 (87.9%) were classified as high solubility drugs while the rest of 4 (12.1%) were classified as low soluble drugs. The rest of 87 drugs (64.4%) were classified according to the ACD/Labs predicted soluble, of which, 66 (75.9%) were classified as high soluble drugs and 21 (24.1%) drug were assigned to low solubility class drugs (Table 1).

Permeability correlation and class assignment

Kasim and colleagues used metoprolol as internal standard indicating high permeability (14). Palm and colleagues showed that PSA of <60 Å ensured complete intestinal absorption (6); however, Kelder and colleagues showed drug intestinal permeation predominated by passive diffusion and paracellular route for drugs with PSA of less than 120 Å (17). When log D6.0 of −1.48, log P of 1.35, and a relaxed PSA of ≤65 Å were used to indicate high permeability of the 59 drugs in common with the Lindenberg's list, cutoffs correctly predicted the permeability class of 30, 33 and 32 drugs (50.8%, 54.2% and 55.9%), respectively (Supplementary table 3). The fraction absorbed (Fa) of metoprolol (≥95%) is considerably even more conservative than permeability criteria (≥90%) of the Food and Drug Administration (FDA) (18). The use of labetalol as high permeable internal standard (Fa ≥90%) was evaluated using log D6.0 of −0.42, Log P of 2.31, and PSA of ≤95.6 Å. These cutoffs correctly predicted the permeability class of 38, 32, and 36 drugs (64.4%, 54.2% and 61%), respectively.
Supplementary table 3

Comparison of Permeability prediction based on log P, log D and PSA, by using metoprolol or labetalol as internal standard.

DrugLog PLog D6.0PSAInternal standard: MetoprololInternal standard: LabetalolReliable experimental solubilityΘ


Log P cutoff “1.35”Log D6.0 cutoff “−1.48”PSA cutoff “65”Log P cutoff “2.31”Log D6.0 cutoff “−0.42”PSA cutoff “95.6”
Abacavir0.720.0396.95LowLowLowLowHighLowLow
Acetylsalicylic Acid1.19−1.2463.6LowLowHighLowLowHighLow
Aciclovir−1.76−1.76109.83LowLowLowLowLowLowLow
Allopurinol−1.33−3.8174.69LowLowLowLowLowHighLow
Amiloride1.081.07156.79LowLowLowLowHighLowHigh
Atenolol0.1−2.7384.58LowLowLowLowLowHighLow
Captopril0.27−2.0296.41LowLowLowLowLowLowLow
Carbamazepine2.672.6746.33HighHighHighHighHighHighHigh
Chloramphenicol1.021.02115.38LowLowLowLowHighLowLow
Chloroquine4.691.228.16HighLowHighHighHighHighHigh
Cimetidine0.26−1.14114.19LowLowLowLowLowLowLow
Cloxacillin2.53−0.81138.04HighLowLowHighLowLowLow
Codeine1.2−0.9941.93LowLowHighLowLowHighLow
Colchicine0.920.9283.09LowLowLowLowHighHighLow
Cyclophosphamide0.230.2351.38LowLowHighLowHighHighHigh
Dapsone0.940.9494.56LowLowLowLowHighHighHigh
Diazepam2.962.9632.67HighHighHighHighHighHighHigh
Digoxin0.850.85203.06LowLowLowLowHighLowHigh
Doxycycline−0.54−3.06181.62LowLowLowLowLowLowHigh
Ergotamine3.581.99118.21HighHighLowHighHighLowLow
Fluconazole0.50.571.79LowLowLowLowHighHighHigh
Furosemide30.26131.01HighLowLowHighHighLowLow
Griseofulvin3.533.5371.06HighHighLowHighHighHighHigh
Hydralazine10.5663.83LowLowHighLowHighHighLow
Hydrochlorothiazide−0.07−0.07135.12LowLowLowLowHighLowLow
Ibuprofen3.722.1237.3HighHighHighHighHighHighHigh
Indinavir2.882.76118.03HighHighLowHighHighLowLow
Levodopa−0.22−0.27103.78LowLowLowLowHighLowHigh
Levonorgestrel3.923.9237.3HighHighHighHighHighHighHigh
Levothyroxine5.933.3892.78HighHighLowLowHighHighLow
Metformin−2.31−4.3188.99LowLowLowLowLowHighLow
Methyldopa0.12−2.37103.78LowLowLowLowLowLowLow
Metronidazole−1.01−1.0178.94LowLowLowLowLowHighHigh
Nelfinavir6.985.44127.2HighHighLowLowHighLowLow
Nifedipine2.972.96110.45HighHighLowHighHighLowHigh
Nitrofurantoin−0.4−0.41120.73LowLowLowLowHighLowHigh
Paracetamol0.340.3449.33LowLowHighLowHighHighLow
Penicillamine0.93−1.57102.12LowLowLowLowLowLowLow
Penicillin V1.88−1.47121.24HighLowLowLowLowLowHigh
Phenobarbital1.671.6675.27HighHighLowLowHighHighHigh
Phenytoin2.522.5258.2HighHighHighHighHighHighHigh
Prednisolone1.491.4994.83HighHighLowLowHighHighHigh
Primaquine2.67−0.4160.17HighLowHighHighHighHighHigh
Promethazine4.782.0431.78HighHighHighHighHighHighLow
Propranolol3.10.2841.49HighLowHighHighHighHighHigh
Propylthiouracil1.371.3673.22HighLowLowLowHighHighLow
Pyrazinamide−0.37−0.3768.87LowLowLowLowHighHighHigh
Pyridostigmine−4.31−4.3129.54LowLowHighLowLowHighLow
Riboflavin−2.02−3.48155.05LowLowLowLowLowLowHigh
Ritonavir5.285.28202.26HighHighLowLowHighLowLow
Salbutamol0.01−2.8472.72LowLowLowLowLowHighHigh
Saquinavir4.442.84166.75HighHighLowHighHighLowLow
Stavudine−0.86−0.8678.87LowLowLowLowLowHighHigh
Sulfamethoxazole0.890.49106.6LowLowLowLowHighLowHigh
Theophylline−0.17−0.1869.3LowLowLowLowHighHighHigh
Thiamine−1.61−1.65100.27LowLowLowLowLowLowLow
Trimethoprim0.79−0.42105.51LowLowLowLowHighLowHigh
Valproic Acid−1.61−1.65100.27LowLowLowLowLowLowHigh
Zidovudine−0.53−0.5391.23LowLowLowLowLowHighHigh
Comparison of Permeability prediction based on log P, log D and PSA, by using metoprolol or labetalol as internal standard. When WHO's classification (16) where compared with the current classification in table 1; of the 80 drugs in common, 62 drugs (77.5%) were classified in the same permeability classes, whereas, of the 18 drugs for which the permeability classes were different, 11 could be correctly classified by their PSA values (Supplementary Table 2). To further verify the suitability of the permeability class assignment based on log D, the Caco-2 monolayer permeability (Papp) values for a total of 22 drugs which were in common with a previous work (13) were obtained; these values were basically compiled from the literature. The Papp value for labetalol was obtained from literature (15). Log D6.0 correctly predicted the permeability class for 18 (81.8%) of the 22 drugs (Supplementary table 4). Furosemide, hydrochlorthiazide, saquinavir, and sulphasalazine were false positives. Similarly, the PSA of ≤95.6 Å (PSA of labetalol) correctly predicted the permeability class for 18 (81.8%) of the 22 drugs (Supplementary table 4). Acetylsalicylic acid, atenolol and zidovudine were false positives, whereas, digoxin was a false negative. The PSA of ≤65 Å correctly predicted only 15 (68.2%) out of the 22 drugs compared. In the study of Kasim and colleagues, the log P of metoprolol correctly predicted 18 of 28 (64%) drugs (5). Permeability data correlation: Log D6.0 ACDLabs, PSA and experimental Caco-2 permeability coefficient (Papp). Calculated log D values at pH 6 using ACD/Labs Taken from ref. 15; Ж taken from ref. 19 Ref: reference; c: correct; fp: false positive; fn: false negative. The permeability classes were assigned using log D6.0 in comparison to labetalol which was used as internal standard. In this classification, 128 (94.8%) of the 135 drugs on the NEML were classified, of these, 83 (64.8%) were assigned in high permeability, while the rest of 45 (35.2%) were assigned in low permeability classes. The rest of the 7 (5.2%) were classified according to their PSA values. Of these 2 (28.6%) were classified as high permeability drugs, while the rest of 5 (71.4%) were classified as low permeability drugs. The final BCS classification of the 135 orally administered drugs on the NEML is given in table 1 and class distribution is shown in figure 1.
Figure 1

Biopharmaceutical classification system with drugs on the list of national essential medicines of Pakistan.

Biopharmaceutical classification system with drugs on the list of national essential medicines of Pakistan. Literature often reported solubility data at room temperature. In contrast, the current solubility classification methodology yielded an acceptable accuracy of 86.4% and 78.3% for ACD/Labs and Drugbank solubility values respectively. Moreover, the current classification of solubility criteria were conservative since the solubility usually increases as a function of temperature, therefore, the solubility values at 37°C would be higher than the values used. In vivo human permeability investigations are expensive in terms of financial resources and technical allocations; and moreover are time consuming. Several reports described a certain correlation between physicochemical properties of drug molecules with intestinal absorption (6, 19–22). Linnankoski and colleagues suggested that passive diffusion predominates the routes of intestinal administration for the majority of the drugs (20). Although influx and efflux transporters have an important role in the absorption of some drugs, interestingly, for the majority of drugs the active transport is actually negligible (20). Most of the drugs available in the market are ionizable molecules; therefore, passive diffusion of these ionizable drugs is partly governed by their pKa values. Consequently, log D at physiologically relevant pH should better reflect the overall distribution (ionized and unionized) of a drug (22, 23). Recently, labetalol was suggested as a better internal standard in the permeability comparisons (24). The effective intestinal permeability (Papp) is typically the parameter reflecting both the rate and extent of intestinal absorption. In the current classification, labetalol was used as internal standard. In accordance with results of this study, Winiwater and colleagues found a correlation between Papp, log D at pH of 5.5, PSA and hydrogen bond donors, the use of log D6.0 gave better predictions than log P (22). Similarly, Linnankoski and colleagues established a correlation between the intestinal absorption rate constant (Ka) with log D6.0 and PSA (20).

CONCLUSION

Within the limitations of our investigation, the following conclusions can be drawn. First, log D showed better prediction capability than log P. Second, metoprolol was conservative permeability internal standard as compared to labetalol. Finally, models combining log D and PSA can have the best permeability prediction capabilities.
Supplementary table 4

Permeability data correlation: Log D6.0 ACDLabs, PSA and experimental Caco-2 permeability coefficient (Papp).

DrugPapp**Permeability classLog D6.0Permeability classPredictionPSA cutoff “95.6”PredictionPSA cutoff “65”PredictionLog P cutoff “1.35”PredictionLog P cutoff “2.31”Prediction
Acetylsalicylic acid2.4×10−6Low−1.24LowcHighfpHighfpLowcLowc
Atenolol5.3×10−7Low−2.73LowcHighfpLowcLowcLowc
Carbamazepine2.15×10−5High2.67HighcHighcHighcHighcHighc
Chlorpheniramine1.6×10−5High0.49HighcHighcHighcHighcHighc
Cimetidine1.37×10−6Low−1.14LowcLowcLowcLowcLowc
Dexamethasone2.34×10−5High1.87HighcHighcLowfnHighcLowfn
Diazepam3.34×10−5High2.96HighcHighcHighcHighcHighc
Digoxin5×10−5High0.85HighcLowfnLowfnLowfnLowfn
Diltiazem4.9×10−5High2.64HighcHighcLowfnHighcHighc
Furosemide3.33×10−6Low0.26HighfpLowcLowcHighfpHighfp
Griseofulvin3.68×10−5High3.53HighcHighcLowfnHighcHighc
Hydrochlorthiazide5.1×10−7Low−0.07HighfpLowcLowcLowcLowc
Ibuprofen5.25×10−5High2.12HighcHighcHighcHighcHighc
Indomethacin2.04×10−5High0.3HighcHighcLowfnHighcHighc
Labetalol1.5×10−5Ref−0.42HighcHighcLowfnHighcHighc
Phenytoin2.67×10−5High2.52HighcHighcHighcHighcHighc
Propranolol2.75×10−5High0.28HighcHighcHighcHighcHighc
Quinine2.04×10−5High0.54HighcHighcHighcHighcHighc
Saquinavir5.5×10−7Low2.84HighfpLowcLowcHighfpHighfp
Sulphasalazine1.29×10−7Low0.35HighfpLowcLowcHighHighfp
Theophylline4.47×10−5High−0.18HighcHighcLowfnLowfnLowfn
Verapamil2.63×10−5High2.91HighcHighcHighcHighcHighc
Zidovudine6.93×10−6Low−0.53LowcHighLowcLowcLowc

Calculated log D values at pH 6 using ACD/Labs

Taken from ref. 15; Ж taken from ref. 19

Ref: reference; c: correct; fp: false positive; fn: false negative.

  13 in total

1.  Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs.

Authors:  J Kelder; P D Grootenhuis; D M Bayada; L P Delbressine; J P Ploemen
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

2.  Computational prediction of oral drug absorption based on absorption rate constants in humans.

Authors:  Johanna Linnankoski; Johanna M Mäkelä; Veli-Pekka Ranta; Arto Urtti; Marjo Yliperttula
Journal:  J Med Chem       Date:  2006-06-15       Impact factor: 7.446

Review 3.  Using measured pKa, LogP and solubility to investigate supersaturation and predict BCS class.

Authors:  K J Box; J E A Comer
Journal:  Curr Drug Metab       Date:  2008-11       Impact factor: 3.731

4.  Application of the biopharmaceutical classification system in clinical drug development--an industrial view.

Authors:  Jack Cook; William Addicks; Yunhui Henry Wu
Journal:  AAPS J       Date:  2008-05-24       Impact factor: 4.009

5.  Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors.

Authors:  K Palm; K Luthman; A L Ungell; G Strandlund; F Beigi; P Lundahl; P Artursson
Journal:  J Med Chem       Date:  1998-12-31       Impact factor: 7.446

6.  Molecular properties of WHO essential drugs and provisional biopharmaceutical classification.

Authors:  Nehal A Kasim; Marc Whitehouse; Chandrasekharan Ramachandran; Marival Bermejo; Hans Lennernäs; Ajaz S Hussain; Hans E Junginger; Salomon A Stavchansky; Kamal K Midha; Vinod P Shah; Gordon L Amidon
Journal:  Mol Pharm       Date:  2004-01-12       Impact factor: 4.939

7.  The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted.

Authors:  L Z Benet; C A Larregieu
Journal:  Clin Pharmacol Ther       Date:  2010-07-28       Impact factor: 6.875

8.  A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.

Authors:  G L Amidon; H Lennernäs; V P Shah; J R Crison
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

9.  Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.

Authors:  S Winiwarter; N M Bonham; F Ax; A Hallberg; H Lennernäs; A Karlén
Journal:  J Med Chem       Date:  1998-12-03       Impact factor: 7.446

10.  In vitro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid oral dosage forms.

Authors:  James E Polli
Journal:  AAPS J       Date:  2008-05-24       Impact factor: 4.009

View more
  7 in total

1.  Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents.

Authors:  Maria V Papadopoulou; William D Bloomer; Howard S Rosenzweig; Marcel Kaiser; Eric Chatelain; Jean-Robert Ioset
Journal:  Bioorg Med Chem       Date:  2013-08-20       Impact factor: 3.641

2.  Evaluating Solubility of Celecoxib in Age-Appropriate Fasted- and Fed-State Gastric and Intestinal Biorelevant Media Representative of Adult and Pediatric Patients: Implications on Future Pediatric Biopharmaceutical Classification System.

Authors:  Ramzi Shawahna; Ahed Zyoud; Aseel Haj-Yahia; Raheek Taya
Journal:  AAPS PharmSciTech       Date:  2021-03-01       Impact factor: 3.246

3.  Pediatric Biopharmaceutical Classification System: Using Age-Appropriate Initial Gastric Volume.

Authors:  Ramzi Shawahna
Journal:  AAPS J       Date:  2016-03-02       Impact factor: 4.009

4.  Novel 3-nitro-1H-1,2,4-triazole-based compounds as potential anti-Chagasic drugs: in vivo studies.

Authors:  Maria V Papadopoulou; William D Bloomer; Howard S Rosenzweig; Rachel Ashworth; Shane R Wilkinson; Marcel Kaiser; Grasiella Andriani; Ana Rodriguez
Journal:  Future Med Chem       Date:  2013-10       Impact factor: 3.808

5.  Factors to consider in developing individual pharmaceutical product quality risk profiles useful to government procurement agencies.

Authors:  Wei Xu; Garth Boehm; Qiang Zheng
Journal:  Acta Pharm Sin B       Date:  2015-12-17       Impact factor: 11.413

6.  Biopharmaceutical Characterization and Bioavailability Study of a Tetrazole Analog of Clofibric Acid in Rat.

Authors:  Nancy Vara-Gama; Adriana Valladares-Méndez; Gabriel Navarrete-Vazquez; Samuel Estrada-Soto; Luis Manuel Orozco-Castellanos; Julio César Rivera-Leyva
Journal:  Molecules       Date:  2017-02-14       Impact factor: 4.411

7.  Extraction of Ibuprofen from Natural Waters Using a Covalent Organic Framework.

Authors:  Soraia P S Fernandes; Abdelkarim Mellah; Petr Kovář; Marisa P Sárria; Milan Pšenička; Harik Djamila; Laura M Salonen; Begoña Espiña
Journal:  Molecules       Date:  2020-07-08       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.